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Abstract
Background: Colorectal cancer (CRC) has a high prevalence in western countries. Diagnosis and treatment of CRC is
complex and requires multidisciplinary collaboration across the interface of health care sectors. In Germany, a new
nationwide established program aims to provide quality information of healthcare delivery across different sectors. Within
this context, this study describes the development of a set of quality indicators charting the whole pathway of CRC-care
including data specifications that are necessary to operationalize these indicators before practice testing.
Methods: Indicators were developed following a systematic 10 step modified ‘RAND/UCLA Appropriateness Method’ which
involved a multidisciplinary panel of thirteen participants. For each indicator in the final set, data specifications relating to
sources of quality information, data collection procedures, analysis and feedback were described.
Results: The final indicator set included 52 indicators covering diagnostic procedures (11 indicators), therapeutic
management (28 indicators) and follow-up (6 indicators). In addition, 7 indicators represented patient perspectives. Primary
surgical tumor resection and pre-operative radiation (rectum carcinoma only) were perceived as most useful tracer
procedures initiating quality data collection. To assess the quality of CRC care across sectors, various data sources were
identified: medical records, administrative inpatient and outpatient data, sickness-funds billing code systems and patient
survey.
Conclusion: In Germany, a set of 52 quality indicators, covering necessary aspects across the interfaces and pathways
relevant to CRC-care has been developed. Combining different sectors and sources of health care in quality assessment is an
innovative and challenging approach but reflects better the reality of the patient pathway and experience of CRC-care.
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Introduction
Colorectal cancer (CRC) is the most common cancer and the
second leading cause of cancer related death in Europe [1].
Besides lung and breast cancer it is the third most common cancer
worldwide [2]. Annually, there are approximately 70.000
incidences and 30.000 cases of death of both, men and women,
related to CRC in Germany [3].
The pathway of care for patients with CRC is complex
involving multiple interfaces and multidisciplinary health care
providers in inpatient and outpatient settings, relating to diagnostic
procedures, therapy decision-making, multimodal treatment and
surveillance. Beside the expertise of health care providers,
coordination and communication and a good infrastructure for
surveillance and follow-up are necessary to provide good quality
throughout the entire pathway of care.
Transitions between hospital and ambulatory care are the most
vulnerable parts of the delivery of high quality and safe care,
especially in fragmented health care structures such as are
established in Germany and in the United States [4,5].
Quality of colorectal cancer care is an important clinical and
political issue worldwide [5,6]. As quality-measurement of
processes and outcomes has an important role in many strategies
to improve healthcare, much effort has gone into developing and
applying quality indicators over the last decades [7]. Quality
indicators are defined as measurable elements of practice
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performance for there is evidence or consensus that they can be
used to assess and change the quality of care provided [7]. It is
important that quality indicators meet a range of requirements
such as relevance, validity, reliability and feasibility relating to the
implementation of indicators in routine care [8].
Whereas the development of quality indicators for colorectal
cancer care has been reported in many countries [9–13],
operationalization of these indicators including specification of
data sources, data collection methods and analyzing or practice
testing have been rarely described [14]. Previously developed
quality indicators and quality improvement initiatives have been
focused mainly on surgical treatment reflecting the importance of
primary tumor resection as a curative approach within multimodal
therapy regimens [6]. However, quality assessment from a
comprehensive disease perspective, measuring the quality of
CRC care from patient presentation to postoperative surveillance
and follow-up throughout the entire pathway of CRC-care, is not
yet described [5,13,15].
Patient centered care is as an integral part of evaluating health
care [16] particularly in cancer care [5,17]. Previous literature
shows that professionals’ opinions about high quality care may
deviate from patients’ perspectives, so it is necessary to involve
patients in indicator development [18]. However, many sets of
quality indicators do not include measures of patient centeredness
or experience.
A wide variety of methodological approaches for developing
quality indicators has been reported; however, patient represen-
tatives are mostly not included and practice testing of indicators is
not always provided during the development process [19]. It is also
crucial to test sets of indicators using a testing protocol [20,21].
Therefore, the aim of this study was twofold: First, to develop a
comprehensive set of cross-sectoral quality indicators along the
whole pathway of colorectal cancer care including patient
representatives; Second, to describe important steps towards
practice testing of these indicators such as specification of data
management, analyzing and feedback procedures.
Methods
Setting
Germany has a population of about 82 million inhabitants,
about 90 percent of the population is covered by statutory
insurance (generally under compulsory insurance cover), while
private insurance - to which only civil servants, the self-employed
and high-earning employees have access - covers about 10 percent
of the population. The costs of statutory health insurance are split
roughly 50:50 between employers and employees, with the
government paying for coverage of welfare recipients [22].
Health spending accounted for 11.6% of the gross domestic
product (GDP) in Germany in 2010, more than two percentage
points higher than the Organization for Economic Co-operation
and Development (OECD) average of 9.5%. Still, health spending
as a share of GDP remains much lower in Germany than in the
United States (which spent 17.6% of its GDP on health in 2010)
[23].
The German Health Care system is characterized by the
fragmentation of care structures with rigid financial barriers
between ambulatory and hospital care. The almost 250 health
insurance funds and their umbrella organizations regulate the
system. In the ambulatory sector fund members have the right of a
free choice of doctor and can consult a specialist directly [22].
The Federal Joint Committee (G-BA) regulates the healthcare
system independently under the supervision of the Ministry of
Health. In 2009, the G-BA established a comprehensive program
for quality improvement across healthcare sectors in Germany
(‘Sektorenu¨bergreifende Qualita¨tssicherung im Gesundheitswesen’
or ‘SQG’) and commissioned an independent institution, the
Institute for Applied Quality Improvement and Research in
Health Care (AQUA-Institute) [24] to develop national cross-
sectoral quality measures, data collection procedures and analytic
procedures to feed-back measurement results to health care
providers to stimulate quality improvement [25]. As the SQG
quality program is obligatory and is nationwide, health care
providers in both sectors are required to record and transfer
quality information.
Development process
The study was carried out between January 2010 and
December 2011. The AQUA-institute processed this task in
collaboration with the ‘Department of General Practice and
Health Services Research’ at the University Hospital at Heidel-
berg. A ten step [25] modified ‘RAND/UCLA Appropriateness
Method’ [26] was applied to develop the quality measures. This
procedure included a scoping workshop with experts, structured
literature search to identify quality indicators, two rounds of panel-
ratings, design of measure specifications and the delivery of a final
report to be approved by the G-BA (Table 1).
Scoping workshop
Members of medical societies and interest groups involved in
the CRC-care process were openly invited to a scoping workshop
by post and via a website announcement. 55 experts of various
clinical professions such as surgery, gastroenterology, oncology,
pathology, family medicine, human genetics, epidemiology,
nursing and patient representatives participated in the meeting.
Representatives of the federal association of sickness funds and
other stakeholders of the German healthcare system reported on
quality improvement initiatives. The aim of the workshop was to
collect and synthesize knowledge of experts across the CRC
healthcare interfaces.
Structured search for indicators
The search consisted of 3 steps: 1) a preliminary search to get an
overview about current colorectal cancer care and the situation in
Germany (Table S2), 2) the main systematic literature search to
identify internationally applied quality indicators (Tables S3, S4,
S5, S6) and 3) a search of international agencies and indicator
databases to identify quality indicators concerning colorectal
cancer care (Table S7).
In a preliminary search, Cochrane Database of Systematic
Reviews, guideline databases, Medline and oncology journals were
searched for guidelines and systematic reviews on CRC and a final
search model for a systematic search in Medline was developed.
We identified 28 papers from the ‘Cochrane Colorectal Cancer
group’ and 45 international guidelines on CRC including one
German evidence-based guideline [3], 1 Health Technology
Assessment (HTA)- report and 25 additional papers that
highlighted the German perspective.
The structured search was carried out from February to March
2010. We searched MEDLINEH (from 1998 to March 2010)
systematically using a predefined search strategy (Table S3) and
identified 4,942 potentially relevant abstracts (Table S4). Addi-
tionally, 41 relevant publications were found by hand search of
peer reviewed oncology journals. Paired reviewers (researchers
including physicians and methodologists) screened the abstracts
independently using predefined inclusion and exclusion criteria
(Table S5) and ordered the full-text when either reviewer selected
it for inclusion. The full-texts were abstracted for quality indicators
CRC-Quality Measures across Healthcare Sectors
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using self-developed and piloted abstraction forms. Finally, 99
publications (Table S6) met inclusion criteria, of which 289 quality
indicators for the diagnosis and treatment of colorectal cancer
were extracted (Figure 1).
A structured search of indicator agencies worldwide (73
previously identified agencies were retrieved for indicators)
identified 419 quality indicators (Table S7) in various dimensions
[27]. Indicators were also extracted from national grey literature,
such as professional-society documents (German Cancer Society)
or government reports. After removing duplicates, 52 quality
indicators remained (Figure 2).
Preparing candidate indicators for expert panel ratings
The resulting 341 quality indicators composed of 289 indicators
from systematic literature search and 52 indicators from indicator
agencies, were translated into German and allocated to the clinical
dimensions ‘diagnosis’, ‘therapy’, ’management/coordination of
care’, ‘patient perspective’ and ‘outcome’ as appropriate. The
indicators were drafted to 210 self-developed standardized
templates providing original indicator wordings (English mostly)
and German translations. Indicators that differed from each other
only slightly in wording were subsumed to one single indicator
template providing the various original wordings. Additionally,
templates included categories for a short description of the
indicator, the definition of numerator and denominator, inclusion
and exclusion criteria, indicator level targets and the type of the
quality indicator relating to structure, process or outcome. Sources
of the indicators and evidence from literature or guidelines were
also provided. Finally, 210 templates summarized 341 quality
indicators in the clinical dimensions diagnosis (22), therapy (104),
management and coordination of care (47), patient perspective
(31) and outcome (6).
Expert panel ratings
The expert panel ratings were carried out between June and
September 2010. All medical societies involved in diagnosis and
Table 1. Phases and steps in the development and testing of indicators for colorectal cancer care.
Phases Steps
Planning 1. Scoping workshop
- Collecting existing knowledge and practice
2. Structured search
- Structured literature search using a predefined search model
- Structured search in indicator agencies
3. Organization of the assessment panel
- 11 multidisciplinary experts and 2patient representatives
4. Preparation of quality indicators for the panel assessment
- Defining of the indicator (numerator, denominator)
- Inclusion and exclusion criteria
- Target levels or standards
- Type (process, outcome, intermediate outcome, structure)
- Sources
- Evidence
Rating 5. Preliminary meting
- Overview about the development procedures
- Providing of indicator templates
6. Rating rounds
- Validity – postal and meeting
- Feasibility – postal and meeting
Operationalizing 7. Specification of measures
- Unit of analysis (patient, hospital, provider)
- Data sources (administrative data, medical record data, survey)
- Risk adjustment
- Responsibility for indicator results
- Data sources
- Data collection procedures
- Analytical plan
- Feedback strategies
Approval 8. Approval of the final report by the G-BA
Piloting 9. Feasibility test
10. Field testing
doi:10.1371/journal.pone.0060947.t001
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Figure 1. Systematic literature search - Flow chart.
doi:10.1371/journal.pone.0060947.g001
Figure 2. No of quality indicators identified by systematic search (allocated to the OECD quality model dimensions) [24].
doi:10.1371/journal.pone.0060947.g002
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Table 2. Quality indicators of CRC care included in the final set (for detailed description see Table S1).
Clinical Dimension Indicator Data sources* Feed-back**
Diagnostic procedures
and staging
1 Availability and constitution of multidisciplinary tumor boards/ambulatory
multidisciplinary teams
1; 2;3 11
2 Pre-therapeutic assessment of CRC-patients by tumor boards/ambulatory
multidisciplinary teams
5 or 6 11
3 Tumor boards/ambulatory multidisciplinary teams with expertise in
metastatic surgery
1;2; 3 11
4 Availability and content of a preoperative colonoscopy report 4 10
5 Colonoscopy reports with documentation of specific quality aspects 7 10
6 Pre-therapeutic availability of a histo-pathologic diagnosis (tumor biopsy) 1;4 or 6 10
7 Pre-therapeutic liver imaging in CRC patients 1;4 or 6 10
8 Pre-therapeutic rigid rectoscopy in RC-patients 1;4 or 6 10
9 Pre-therapeutic staging using cTNM-categories in RC-patients 1;4 or 6 10
10 Pre-therapeutic pelvis imaging using multi-slice CT or high-resolution MRI in RC-patients 1;4 or 6 10
11 Pre-therapeutic imaging of liver and lungs using CT or MRI in
CRC-patients with liver metastases
1;4 or 6 10
Pre-operative
manage-ment
12 Pre-operative assessment of bowel; urinary and sexual function in RC-patients 1; 8 10
13 Assessment of Bethesda-criteria in CRC-patients 1; 5
14 Pre-operative stoma education where appropriate 1; 5
15 Preoperative marking of stoma localization 1; 5
Radio-
(chemo)therapy
16 Neo-adjuvant radio(chemo)therapy in RC-patients 1; 5 11
17 Radiotherapy according to quality standards of the German Society of




18 Antibiotic prophylaxis before CRC-surgery 1;5 or 7 10
19 En bloc resection in case of tumor adherence to other organs 1;3 or 7 10
20 Intraoperative exploration of liver and peritoneal lining 1;3, or 7 10
21 Intraoperative local dissemination of tumor cells 1;3 or 7 10
22 Total/partial mesorectal excision (TME/PME) in RC-patients 1;3 or 7 or 6 10
23 Abdominal perineal resection (APR) in RC-patients 1;3 or 7 or 6 10
24 Major anastomotic leakage after elective CRC-surgery 1; 3 or 7 10
25 Surgical re- interventions after CRC-surgery 1;3 or 7 10
26 Examination of least 12 lymph nodes 1;2; 3 10
27 Rate of local R0-resections in CRC-patients 1;2; 3 10
28 Rate pT1 carcinomas in CRC-patients 1;2; 3 11
29 Liver- and lung-metastasectomy in patients with stage IV CRC 1;2; 3
30 Documentation of distal tumor-free margin in RC-patients 1;2; 3 10
31 Mesorectal CRM-positive (CRM ,1mm) radical surgical resection in RC-patients 1;2; 3
32 Quality of Total Mesorectal Excision (TME) 1;2; 3
33 Pathology reports following quality standards of the German Society of Pathology 1;2; 3 or 7
41 Examination of microsatellite-instability in CRC-patients younger than 50 years 1;2; 3
Post-operative
manage-ment
35 Post-operative assessment of bowel; urinary and sexual function in RC-patients 8 10
36 Providing of information and instructions about stoma management




37 Adjuvant chemotherapy in patients with stage III CC 1;2; 5 11
38 Time interval between surgery and starting adjuvant chemotherapy
in patients with stage III CC
1;2; 5
39 Documentation of chemotherapy treatment summary in medical records and passing
on this information to the patient and to the physician providing surveillance
1;2; 3 10
Sur-veillance 42 Postoperative colonoscopy within 6 months in patients with incomplete
preoperative colonoscopy
1;2; 5 or 6 11
CRC-Quality Measures across Healthcare Sectors
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treatment of CRC were asked to inform their members to apply
for the panel. Furthermore, an invitation was announced at the
scoping workshop in Heidelberg and also provided openly via
internet [24]. From 77 applications for the panel, 14 experts were
selected according to predefined criteria aligned to including the
most relevant disciplines in the pathway of CRC care. If experts
were equally qualified, the panel candidate was drawn randomly
by lot. Finally, these multidisciplinary experts from inpatient and
outpatient care were chosen for the panel: One family physician,
one gastroenterologist, two clinical oncologists, one psychothera-
pist/psycho-oncologist, three visceral surgeons, one pathologist,
one representative of a regional consortium/working group for
quality assurance, one expert for quality assurance in oncology,
and one representative of a regional cancer registry. Additionally,
two patient representatives nominated by the G-BA completed the
panel membership. As no radiation oncologist applied to the
panel, a radiation oncologist was nominated by the German
Society of Radiation Oncology (DEGRO) to give advice to the
panel. All panel members had to declare conflicts of interests in a
written form.
The panel rating was performed in two rounds consisting of a
postal rating and a face-to-face panel meeting in each round. The
voting of all members of the panel was counted equally.
In round one, panelists rated the content validity in terms of
relevance on a 9-point integer scale with a score of one (not at all
relevant) for the first answer up to nine (very relevant). In the
postal ratings, the quality indicators were rated by each expert of
the panel at home/office and sent back anonymously by return
envelope. The indicator templates provided the opportunity to
give comments to adapt indicators if necessary. At the two-day
panel meeting, the results of the postal ratings from round one
were presented and discussed. If necessary, the quality indicators
were modified to align them to recommendations of the German
evidence based guideline [3] or to the German health care system.
After discussion, each quality indicator was re-rated.
In round two, the same procedures were applied to rate the
feasibility of the indicators.
Analyses of the ratings were based on the ‘RAND/UCLA’
Appropriateness Method [26]. For each quality indicator overall
panel median scores and the level of agreements within the panel
were calculated. Median scores of 7–9 and consensus of more than
75% were defined as ‘‘agreement’’, the quality indicator was
classified as valid. A median score of 1–3 with an agreement of
more than 75% was defined as not valid. In the feasibility rating, a
quality indicator with a median score of more than 4 was defined
as feasible. All statistical analyses were performed with SPSS-
Statistics/PASW (Predictive Analysis Soft Ware) Vs 18.
Designing of measure specifications
For each indicator, data sources and required data fields were
specified including trigger criteria to identify patients for the
quality assurance program, data fields to create the indicator and
data fields that were required for risk adjustment where
appropriate. Trigger criteria were derived from the International
classification of Diseases (ICD-10 GM) – codes that were available
in the ambulatory and in the hospital sector, and from process
codes of the hospital (OPS codes) and ambulatory (fee schedule
items) reimbursement systems. Furthermore, data fields were
described that had to be additionally recorded for quality-
assurance purposes. Specifications for data flow and analyses were
provided. To create indicators requiring data from both the
ambulatory and the hospital sector, it had to be ensured that all
data would come together in a separate trusted center that had to
assign this information to a certain patient and to forward these
data anonymously to the AQUA-institute for analysis. To collect
data relating to the indicators on patients’ perspectives, procedures
Table 2. Cont.
Clinical Dimension Indicator Data sources* Feed-back**
43 Postoperative surveillance as recommended in the German
S3 guideline
1; 2; 4 or 6
Patient
perspec-tive
40 Delivery of a written plan for pain management in CRC-patients
where appropriate
8 10
44 Sharing the decision with the patient regarding therapeutic
procedures
8 10
45 Opportunities to ask the specialists questions 8 10
46 The patient is offered contact with a companion in distress 8 10
47 The patient knows, which activities are allowed at home 8 10
48 The patient knows, which side effects or complications to be aware
of at home
8 10
49 The patient knows, when to contact the general practitioner
or specialist
8 10
Outcomes 50 5-year overall survival in CRC-patients 9 11
51 5-year local recurrence RC-patients 1; 2; 3 or 6
52 30-day-mortality after primary CRC-surgery 9 10
53 Assessment of quality of life with a specific instrument in
CRC-patients
8 11
*Data sources: 1: Inpatient administrative and/or reimbursement data (OPS-codes), 2: Outpatient administrative and/or reimbursement data (fee schedule items), 3:
Prospectively collected clinical data, 4: Retrospectively collected clinical data during tracer procedure, 5: Medical record, 6: Implementation of new procedure codes:
OPS-codes (hospital) or fee schedule items (ambulatory sector), 7: Peer review, 8: Patient survey, 9: Administrative data (sickness funds).
**Feedback: 10: Healthcare provider level – Benchmarking feedback reports with ‘structured dialogue’ in case of poor results, 11: Area level – multidisciplinary
discussion.
doi:10.1371/journal.pone.0060947.t002
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for random selection of patients and implementation of patient
surveys during the therapy course were described. Peer review
auditing as an innovative concept of data collection methods was
described for indicators reflecting the quality of reports that
summarize important clinical findings such as the colonoscopy-
report or the surgery-report. Data specifications and data flow
models were discussed with the G-BA and revised before being
included in a final report.
Results
Final set of quality indicators
The final set included 52 quality indicators (Table 2 and
Table S1) representing significant in- and outpatient procedures
along the entire pathway of CRC care. The set of indicators
described pre-therapeutic diagnostic procedures (11 indicators),
therapeutic procedures (28 indicators), surveillance (2 indicators)
and outcomes (4 indicators). Furthermore, 7 indicators were
related to patient specific issues (Table 2).
Diagnostic procedures
In line with the German evidence-based guideline [3], all
relevant diagnostic procedures such as colonoscopy, biopsy or
imaging techniques were covered by the indicators. Most of these
indicators were process indicators, measuring whether a diagnostic
procedure has been performed such as a pre-therapeutic tumor
biopsy (indicator 7). Additionally, the diagnostic indicator set
included technical measures pertaining to specific details of a
procedure such as the availability of standardized colonoscopy
reports indicating not only performance but also the quality of
colonoscopy-performance and report (indicator 5). The availability
of multidisciplinary tumor boards for therapy decision-making, as
an example for a cross-sectoral indicator, was also included
(indicator 1 and 2).
Therapeutic indicators
Therapeutic procedures comprised surgery procedures, pre-
and post-therapeutic management and the application of radio-
therapy and chemotherapy. Most indicators concerned surgical
processes, reflecting the importance of colorectal resection for
cancer as a curative approach. Beside process measures, technical
measures such as the delivery and quality of a total mesorectal
excision (TME) in patients with RC were also included (indicators
22 and 32). The assessment of the pre- and postoperative
functional bowel status (indicators 12 and 35) reflected patient
relevant issues. The quality of staging procedures was described by
two indicators including the quality of the pathology report
according to the standards of the ‘German Pathology Society’.
Radiotherapy was represented by two indicators (indicators 16 and
17), with one describing a technical measure providing informa-
tion about the quality of radiotherapy performance (indicator 17).
Three general indicators were related to chemotherapy (indicators
37, 38, 39). No technical measure for chemotherapy was
identified.
Follow-up indicators were related to surveillance colonoscopy
(indicator 42) and other diagnostic procedures recommended for
the early detection of disease recurrence (indicator 43). Outcome
indicators were related to mortality rates (indicator 50 and 52),
disease recurrence for RC (indicator 51) and the quality of life as a
patient related outcome indicator (indicator 53).
Across these processes, 7 indicators representing patients’
perspectives completed the set: These indicators were related to
patient information, shared decision-making, support, pain man-
agement and follow-up management.
Excluded indicators
Indicators were excluded during the panel rounds for several
reasons: Some indicators were rated not valid as they were deemed
to be not specific enough for CRC, such as indicators addressing
colorectal surgery in general. Other indicators were seen as
duplicates of other included indicators and therefore redundant.
Furthermore, indicators were excluded if their measurement was
assumed to be very resource intensive such as the proportion of
RC-patients in appropriate UICC-stages receiving adjuvant
chemotherapy without having received neo-adjuvant radio (che-
mo) therapy before cancer resection. Indicators reflecting patients’
perspectives were suggested to be difficult to assess and to feed-
back to providers as indicator results were not unambiguously
attributable to a specific healthcare provider.
Indicator 34, concerning pain management, was excluded by
AQUA after the panel rounds, as this issue was already addressed
in a generic part of the patient survey within all SQG programs
[24].
Operationalization of indicators
To identify eligible patients for inclusion in the CRC quality
assurance program, two tracer events were defined: 1) primary
tumor resection delivered in hospital and 2) neo-adjuvant
chemotherapy that can be provided either ambulatory or in
hospital. These tracer procedures were used to index eligible
patients for follow up. Diagnostic procedures and findings prior to
these tracer events had to be recorded retrospectively in the
medical charts.
We identified four sources of quality information to be used in
combination to create the quality indicators: first, patient charts -
requiring additional documentation on clinical patient informa-
tion, such as co-morbidities; second, administrative and reim-
bursement inpatient data (ICD codes and OPS-codes) and
outpatient data (ICD codes and fee schedule items) to collect
information on diagnoses and procedures; third; administrative
data from sickness-funds, mainly to collect information on vital
status and fourth, patient survey data to assess patients’
perspectives. Data abstraction protocols were developed. Further-
more, a method to arrange patient surveys including self-
developed questionnaires and validated instruments for the
assessment of quality of life and functional bowel status were
developed.
Feedback procedures
Two groups of feedback procedures were identified. First,
indicator results that could be ascribed unambiguously to
healthcare providers or facilities were targeted to be embedded
in established feedback procedures within the German SQG-
program [24]. These procedures included the provision of a
benchmarking quality report and a ‘structured dialogue’ with
healthcare providers achieving poor results to identify quality
problems.
Providing feedback for the second group of indicators, which
reflected cross-sectoral multidisciplinary coordination and shared
responsibilities such as the time period up to starting chemother-
apy after surgical resection, was more complex. For this group of
indicators (area indicators) it was proposed to address feedback,
not to single healthcare providers or facilities but, to define
reference regions such as diversion areas of hospitals and to
provide feedback within multidisciplinary quality circles to
promote quality improvement.
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Final report
The final report comprised the detailed description of the
methodology, the final set of quality indicators and data
abstraction forms for each indicator according to established data
sources and structures within the German healthcare system.
Furthermore, alternative implementation methods were proposed
and discussed in order to reduce data collection time and effort,
such as peer review auditing and the implementation of specific
reimbursement codes (OPS-codes or fee schedule items). The final
report was approved by the G-BA in December 2011.
Discussion
During this study, a set of 52 quality indicators was developed to
reflect the entire pathway of colorectal cancer care. Data
specifications for the final set of indicators were developed,
including various methods of data collection and analyzing and
options for feeding-back measurement results to healthcare
providers and facilities.
The decision of the G-BA to include the clinical domain CRC
in the nationwide mandatory SQG program [24] reflects the
necessity to provide information of the quality of CRC care as one
of the most prevalent cancer entities nationwide [28]. In large
international studies concerning cancer survival, it has been
reported that data delivered form Germany covered only one to
four percent of the national population [29] and the ‘international
Agency for Research on Cancer’ assessed German cancer
incidence rates as not valid [1].
Quality indicator development
Indicators were developed using the ‘RAND/UCLA Appropri-
ateness Method’ [26] that systematically combines scientific
evidence and expert opinion and is proven to be a scientific
sound method of indicator development [7]. Although there were
disagreements between various disciplines within the multidisci-
plinary panel, it was possible to agree a final set of 52 indicators
out of 210 candidate indicators presented to the panel. As
demonstrated in previous literature, the panel composition of
multidisciplinary medical professionals and patient representatives
stimulated interaction during the consensus meetings and led to a
more comprehensive set of indicators [17,30].
As most quality indicators identified in the systematic search
were developed in other countries, they could not be transferred
directly between countries but had to be adapted to the German
healthcare system and to the recommendations of the German S3-
guideline on CRC during the panel process [31,32]. As candidate
indicators were presented in templates that included (where
available) the underlying evidence of the indicator, indicators that
were supported by high-level evidence-based guideline recom-
mendations, were generally agreed unanimously by the panel
members. The various medical disciplines involved in the care
process of CRC were addressed comprehensively in the final set of
indicators. However, clinical oncologists complained of the
imbalance between the number of indicators representing surgery
compared to chemotherapy and claimed a broader focus on
chemotherapy indicators. Although chemotherapy is an essential
component of multimodal therapy regimes for many patients with
CRC, surgical therapy as a curative approach is related to a
broader patient sample (denominator): According to the German
multi-center study, over 90% of CRC-patients receive surgical
treatment [33]. Measurement of chemotherapy indicators is more
challenging as more quality information is needed to define the
appropriate sample (denominator), as chemotherapy is suitable for
only a portion of all patients with CRC and additionally, some of
these patients are either unable to tolerate chemotherapy or refuse
it. Even more information is needed for measuring the application
of special chemotherapy agents or to reflect technical measures
describing details of chemotherapy administration within a variety
of chemotherapy-protocols and a variety of individual response.
These limits led to the conclusion that the measurement of such
indicators is not feasible [34].
It has been questioned whether participants of indicator-rating
panels, usually expert clinicians, are qualified to rate the feasibility
of indicators addressing operational issues of indicator implemen-
tation [35]. It seems to be difficult for panelists to assess the time
and effort of data collection procedures necessary to operationalize
an indicator [35]. Assessment of feasibility may be beyond the
scope of clinical experts, as these are generally not experts for data
collection and analyzes [8]. Therefore, ratings of experts can only
provide a first appraisal concerning the feasibility of indicators,
that has to be confirmed by data collection specialists and tested in
practice using a validated testing protocol [20,21].
Within the SQG program, special emphasis was placed on
patients’ perspectives, resulting in the participation of two patient-
representatives in the multidisciplinary panel and the development
of seven indicators reflecting patients’ perspectives in particular.
This was quite innovative, as it has been shown that patient
participation during indicator development is extremely uncom-
mon [19]. However, as patients’ perspectives of quality assessment
and medically based measures of quality may be different from
each other [36], the inclusion of two patient representatives may
not be sufficient to reflect patients’ view comprehensively. As
similar problems were observed in other SQG procedures,
separate focus groups with patients will be established in future
SQG procedures to supplement SQG-program methods [24,25].
Indicator data specification
In comparison to the role of panel ratings in identifying
consensus and developing valid indicators, it is more challenging
to specify how to measure agreed quality indicators [17];
particularly when measurement requires the combination of data
sources from different healthcare sectors with variable data
availability. Remuneration systems differ considerably between
in- and outpatient settings. Minor problems were caused by
inpatient data collection, where quality information could be
derived from routine data including coded information on
diagnoses based on the International classification of Diseases
(ICD-10 GM) and also coded diagnostic and therapeutic
procedures (OPS-codes). In the German ambulatory sector,
however, OPS-codes were not available. Information on diagnoses
(ICD-10 GM) and procedures (fee schedule items) could be
derived from information systems that are used for clinical and
administrative purposes by healthcare providers [25].
Quality measurement of follow-up procedures is resource
intensive. First experiences in Germany concerning follow-up
measurement were made with liver transplant donees whose follow
up rates were only 67.5% [37]. In our study, it was proposed to use
administrative data from sickness funds as the source for
information on patients’ vital status. As about ninety percent of
the German population is covered by the statutory health
insurance system (SHI), these data represent an innovative method
for measuring risk adjusted long-term outcomes [37,38].
Practice testing prior to usage of quality indicators is an
important step to assess them against the required attributes of
quality indicators such as validity, reliability, feasibility or
sensibility to change [7]. As demonstrated in previous literature,
only 10 to 20% of quality indicators developed for different clinical
conditions have been measured during practice tests [8]. Although
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protocols for indicator practice testing are available [20,21],
technical specifications of measurement are sparse; even though
this is an important step in preparing practice tests [39]. This
includes also taking confounding factors into account due to case
mix in hospitals and socio-demographic variables [8]. Adjustment
for socio-demographic variables and case mix is very important for
reliable interpretation of indicator results. Otherwise treatment of
high-risk groups may be avoided by health care providers [40].
Although we were able to specify procedures for operationaliz-
ing all 52 indicators in the final set, with a preference for using
routinely collected administrative and clinical data, a large amount
of data remained to be collected by additional data recording for
quality assurance purposes. This was considered by the AQUA-
institute to reduce the feasibility of indicator implementation in
routine settings. To reduce documentation efforts, alternative
designs for data collection were described such as peer review
audits. This method was also suggested to be superior concerning
reliability, as complication rates for instance should not depend on
coding of the treating physician because this is prone for
manipulation. The implementation of new specific process codes
(OPS-codes or fee schedule items) was proposed as another
alternative data collection method that has to be considered and
decided by the G-BA.
Incorporation of results in established quality
improvement strategies
Measurement of quality indicators is not an end in itself; it is the
basis for developing and evaluating quality improvement strate-
gies. In Germany, several quality initiatives are established to
improve the quality of cancer care: The Ministry of Health
established the National Cancer Plan in 2009 with the main focus
on harmonizing treatment across the 16 disparate states [41].
Other quality improvement initiatives on CRC care were focused
mainly on the hospital sector [25] or on colorectal surgery [33].
The challenge is now to integrate the SQG-program into existing
initiatives, for instance the national cancer registries, to avoid
redundant data entry. Therefore, working groups have been
established to harmonize interests of various stakeholders and to
discuss requirements with the G-BA.
Strengths and limitations
The strength of the ‘RAND/UCLA Appropriateness Method’ is
the combination of evidence from literature and experts’ opinions
that enables to provide a set of well-founded quality indicators [7].
The multidisciplinary composition of the panel and the intensive
discussion during the panel meetings resulted in a set of indicators
reflecting the entire pathway of care [30]. The nationwide,
politically supported SQG-program has the potential to provide
nationwide valid quality data on colorectal cancer and to link
ambulatory and hospital services. Additionally, the methods
developed in this study can provide case mix adjusted quality
information protecting physicians and hospitals from an unjust
appraisal of their performance.
Limitations of this study are that the harmonization of data
entry and agreement with the G-BA are time consuming processes
that will delay the further development of these indicators such as
feasibility field testing and the roll out of the program.
Conclusions
In Germany, a set of 52 quality indicators, covering all relevant
aspects of the CRC care processes has been developed that address
cross-sectoral interfaces. Combining different sectors and sources
of health care in quality assessment is an innovative and
challenging approach but reflects better the reality of patient
experiences of CRC, rather than sets of indicators that address
individual sectors (ambulatory or hospital) in isolation. It reflects
the interdisciplinary coordination that embodies CRC-care and
will help address quality improvement across health care
interfaces.
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